| Objective:To explore the ability to improve cognitive impairment in patients with acute schizophrenia and type 2 diabetes mellitus after receiving risperidone combined with modified electrosive therapy（MECT）,and to provide technical support and theoretical basis for the treatment of patients with schizophrenia and type 2 diabetes mellitus.Method:A total of 55 acute schizophrenic patients with type 2 diabetes who were hospitalized in Inner Mongolia Mental Health Center（Inner Mongolia Brain Hospital）from December 2021 to January 2023 were selected as experimental subjects.They were divided into experimental group and control group according to random number table method,and the control group was given risperidone treatment.The initial dose of 1mg/day was adjusted to2-6mg/day according to patients’symptoms,signs and adverse drug reactions.The experimental group was treated with risperidone combined with MECT.Risperidone was used in the same way as the control group.MECT was used once a day for the first three days and once every other day after three days.All scales were trained by professionals and carried out in full accordance with the operation manual.The consistency of each test and evaluation reached a satisfactory level.Data entry was completed jointly by two psychiatrists with the title of attending physician and above.The test group was evaluated before treatment,4 hours after the third MECT treatment and 4 hours after the eighth MECT treatment,Patients’Cognitive function was assessed using the Montreal Cognitive Assessment（MOCA）and the Wisconsin card sorting test（WCST）.while the control group was evaluated at the same time.The Positive and Negative Syndrome Scale（PANSS）was used to evaluate the therapeutic effects of patients.The Treatment Emergent Symptom Scale（TESS）was used to assess patients’adverse reactions during treatment and to monitor their blood glucose.Statistical software SPSS25.0 was used for statistical analysis.Counting data were expressed by frequency and compared by Chi-square test.Measurement data conforming to normal distribution were expressed as"（?）±s".The measurement data of non-normal distribution were expressed as M(P25,P75),and the independent sample rank sum test（Wilcoxon rank sum test）was used,with the test levelα=0.05,that is,P<0.05 was considered statistically significant.Results:（1）There were no significant differences between the experimental group and the control group in gender,age,marriage,years of education,course of schizophrenia,course of diabetes,dose of risperidone and use of hypoglycemic drugs（P>0.05）.（2）There was no significant difference in positive and negative symptom scales,Montreal Cognitive Assessment Scale and Wisconsin card sorting test between the experimental group and the control group before modified electroconvulsive therapy（P>0.05）.（3）At 4 hours after the third modified electroconvulsive therapy,there were differences in naming,attention and delayed recall in the Montreal Cognitive Assessment scale between the experimental group and the control group（P<0.05）,among which there were significant differences in attention（P<0.01）,and the control group was better than the experimental group.There were differences in false response,persistent response and non-persistent error in Wisconsin card sorting test（P<0.05）,and the control group was better than the experimental group.（4）At 4 hours after the eighth modified electroconvulsive therapy,there was a difference in orientation in the Montreal Cognitive Assessment Scale between the experimental group and the control group（P<0.05）,and the experimental group was better than the control group.There were no differences in the Wisconsin card sorting test（P>0.05）,and there were differences in the positive and negative symptom scales（P<0.05）.The test group was better than the control group,and there were significant differences between the two groups compared with the admission（P<0.01）,which were better than the admission after treatment.Conclusions:（1）Risperidone combined with MECT and risperidone alone can improve psychiatric symptoms in patients with type 2 diabetes mellitus with acute schizophrenia,and the combined treatment effect is better.（2）Risperidone combined with MECT in patients with type 2 diabetes mellitus in the acute phase of schizophrenia showed impairments in attention,delayed recall,naming,and cognitive transfer compared with those in the drug alone group.（3）Risperidone combined with MECT in patients with type 2 diabetes at the end of the MECT treatment,the ability of attention,delayed recall,naming,and cognitive transfer in the combined treatment group was restored,and the orientation was better than that in the drug alone group. |
PDF Full Text Request